Review of Beta-Adrenoceptor Drugs in Myocardial Infarction Treatment

This report provides a critical analysis of the use of beta-adrenoceptor drugs in treating myocardial infarction. The report examines the purpose, methods, and findings of relevant research, including the work of Yusuf et al. (1985) and Dondo et al. (2017). The analysis focuses on the effectiveness of these drugs, particularly beta-adrenergic blocking agents, in the treatment of patients following myocardial infarction. The report reviews literature, identifies the research question, and assesses the methodology used, including data collection methods and the presentation of results, considering both short-term and long-term trials. The conclusion of the review is based on the findings of the research papers, with the hypothesis supported, and the implications of the findings are addressed. The report highlights the importance of understanding the impact of beta-adrenoceptor drugs on patient outcomes in the context of myocardial infarction.

Running head: CRITICAL ANALYSIS
Critical Analysis
Student Name
University Name
Author Note

1
CRITICAL ANALYSIS
Beta-adrenoceptor drugs have been used for the effective treatment of acute
myocardial infarction with minimum research available on their benefits (Yusuf et al., 1985).
In the following essay, the purpose and the methods that have been used to evaluate the
benefits will be discussed. The purpose identified in the paper is the relative affectivity of
beta-adrenergic blocking agent following myocardial infarction in patients. Lack of evidence
in their usage is the problem. For the review of the literature, data was obtained from various
literature sources which were relevant to the research question. The review is appropriate
because it tries to benefit the treatment of the patients with a positive outcome of
implementing beta-adrenergic blocking agent. The research is non-directional in nature as it
identifies the existence of the effect of the drug but does not specify whether it improves or
worsen. The research question is finding the effect of the drug on patients suffering from
myocardial infarction. In the review, no specified number of patient was chosen. The
mortality effect of the patients was identified by giving treatment to one group and not to the
other. There is no mention of ethical considerations that were made during the conduction of
the study. The data was collected by patients who had participated in the study and
administered the blockers intravenously and orally. The method of this data collection was
reliable as it identifies the treatment of oral and intravenous administrations (Dondo et al.,
2017). The results are presented in two forms – short term and long term trials with different
forms of treatment being given to the patient. The data was collected for every beta-
adrenergic drug administered to the patient. The results were objective and bound to the data
with relevant comparison to previous studies. The conclusion of the review is based on the
findings that have been found by the research papers with the hypothesis supported. The
implications have been answered and are a result of the findings.

2
CRITICAL ANALYSIS
References
Dondo, T. B., Hall, M., West, R. M., Jernberg, T., Lindahl, B., Bueno, H., ... & Timmis, A.
D. (2017). β-Blockers and mortality after acute myocardial infarction in patients
without heart failure or ventricular dysfunction. Journal of the American College of
Cardiology, 69(22), 2710-2720.
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985). Beta blockade during and
after myocardial infarction: an overview of the randomized trials. Progress in
cardiovascular diseases, 27(5), 335-371.